remsima truxima herzuma yuflyma
Scope
Date
~
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
KOICA donates Celltrion's Herzuma to Ukraine
Celltrion Healthcare Co. said on Monday that Herzuma (ingredient name: Trastuzumab) was dispatched to patients in Ukraine by the Korea International...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion to seek FDA approval for sale of Remsima SC by year-end
Celltrion Inc. said it has confirmed the effectiveness and safety of Remsima SC in its third-phase global clinical trials, conducted on 438 patients...
Nov 28, 2022 (Gmt+09:00)
-
Earnings
Celltrion's Q3 earnings boosted by Remsima sales in Europe
South Korean biopharmaceutical giant Celltrion Inc. announced 654.6 billion won ($478.2 million) in revenue and 213.8 billion won in operating profi...
Nov 09, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare logs record-high Q2 revenue on back of Remsima
Celltrion Healthcare Co., South Korean biopharmaceutical giant Celltrion Inc.’s global marketing affiliate, posted its record-high second-quar...
Aug 17, 2022 (Gmt+09:00)
Latest News
- 1 Lee Jae-myung to meet with top business leaders this week ahead of G7 summit
- 2 Korea to allow non-profits to buy bad consumer loans
- 3 LG to drive future growth in emerging markets with battery prowess
- 4 South Korean President Lee, Japanese Prime Minister Ishiba seek closer ties
- 5 Naver Ventures to plant flag in Silicon Valley with TwelveLabs bet